Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer
Phase 1
Withdrawn
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Fujian Cancer Hospital
- Registration Number
- NCT03380689
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China
PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 214
- Registration Number
- NCT03375515
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China
EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT03341494
- Locations
- 🇨🇳
Fujian Cancer Hospital Radiation Oncology Department, Fuzhou, Fujian, China
🇨🇳Fujian cancer hospital, Fuzhou, Fujian, China
Phase I Study of the Combination of Apatinib and POF
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT03244774
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China
Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment
- Conditions
- SCLC
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2017-08-10
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT03244904
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
Phase 2
Withdrawn
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Fujian Cancer Hospital
- Registration Number
- NCT03222089
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China
Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2017-05-08
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 47
- Registration Number
- NCT03137004
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China
mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA
Not Applicable
- Conditions
- Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction
- Interventions
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT03045770
- Locations
- 🇨🇳
Jianwei Yang, Fuzhou, Fujian, China
Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA
Phase 2
- Conditions
- Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction
- Interventions
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 74
- Registration Number
- NCT03030937
- Locations
- 🇨🇳
Jianwei Yang, Fuzhou, Fujian, China
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC
- First Posted Date
- 2016-09-01
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT02886195
© Copyright 2025. All Rights Reserved by MedPath